Publications
358 results found
Ruiz-Garcia M, Bartra J, Alvarez O, et al., 2021, Cardiovascular changes during peanut-induced allergic reactions in human subjects, Journal of Allergy and Clinical Immunology, Vol: 147, Pages: 633-642, ISSN: 0091-6749
Background: Food allergy is the commonest cause of anaphylaxis. Changes in posture during acute reactions can trigger fatal outcomes, but the impact of allergic reactions on the cardiovascular system in non-fatal reactions remains poorly understood. Objective: To systematically evaluate changes in cardiovascular function during acute allergic reactions to peanut. Methods: Participants underwent double-blind placebo-controlled food challenge topeanut as part of a clinical trial. Changes in hemodynamic parameters (heart rate, stroke volume, blood pressure, peripheral blood flow) and electrocardiogram during food challenges were assessed using continuous monitoring. ClinicalTrials.gov Identifier: NCT02665793 Results: 57 adults (median age 24 (IQR 20-29) years, 53% female) participated; 22 (39%) had anaphylaxis. Acute reactions were associated with significant changes in stroke volume (mean decrease 4.2%, 95%CI 0.8 to 7.6; p=0.03), heart rate (mean increase 11.6%, 95%CI 8.4 to 14.8; p<0.0001) and peripheral blood flow (mean increase 19.7%, 95%CI 10.8 to 28.6; p<0.0001), irrespective of reaction severity. These changes were reproduced at subsequent repeat peanut challenge in 26 participants, and could be reversed with administration of intravenous fluids which resulted in faster resolution of abdominal symptoms. Conclusions: In this first detailed human study of cardiovascular changes during food-allergic reactions, we found evidence for significant fluid redistribution, independent of reaction severity. This provides a sound rationale for optimizing venous return during significant allergic reactions to food. Finally, these data provide a new paradigm for understanding severity in anaphylaxis, where poor outcomes occur due to a failure in compensatory mechanisms.Ruiz-Garcia et al 5 Clinical Implication: Significant changes in cardiovascular function, including decreased stroke volume, occur during peanut-induced allergic reactions in adults irrespective of severit
Shamji MH, Boyle RJ, 2021, What does climate change mean for people with pollen allergy?, CLINICAL AND EXPERIMENTAL ALLERGY, Vol: 51, Pages: 202-205, ISSN: 0954-7894
Boyle RJ, Shamji MH, 2021, Allergy prevention, Clinical and Experimental Allergy, Vol: 51, Pages: 4-5, ISSN: 0954-7894
Agache I, Layhadi JA, Kirtland M, et al., 2021, Mechanisms of Allergy, Encyclopedia of Respiratory Medicine, Second Edition, Pages: 435-447, ISBN: 9780081027233
The rapid rise in the prevalence of allergic diseases during the last decades has triggered extensive research to better understand the allergic endotype and to establish new preventive and therapeutic strategies. Allergic endotype occurs in association with an atopic background and is a sub-endotype of type 2 immune response which is driven by type-2 innate lymphoid cells and T-helper 2 cells releasing IL-4, IL-13 and IL-5. The sensitization phase is followed by the elicitation phase (early- and late-phase responses), upon re-exposure to allergen. Effector cells, mediators, cytokines and chemokines work in a complex network resulting in specific allergic symptoms.
Layhadi JA, Palmer E, Sharif H, et al., 2021, Current Drug Treatments for Allergy, Encyclopedia of Respiratory Medicine, Second Edition, Pages: 477-490, ISBN: 9780081027233
Allergic diseases remain to be a substantial socioeconomic burden with increasing prevalence worldwide. Despite considerable efforts to identify safe and effective treatment, the lack of validated biomarkers and the existence of a complex disease phenotype and endotype remains the main challenge to advance precision medicine. Understanding the immunological and molecular mechanisms underlying the development of allergic diseases and pathways that drive immune tolerance is crucial in designing therapeutic approaches for treating allergic diseases. At present, allergen-specific immunotherapy and biologicals that target key molecules driving type-2 response (IgE, IL-4, IL-5 and IL-13) are used in the clinic. A few other candidate drugs and a combination of biologics as an adjunct to allergen immunotherapy are currently being tested in clinical trials to assess their safety and efficacy. This chapter describes the underpinning mechanisms of allergic diseases and associated therapeutic options available in the clinic, focusing on asthma, atopic dermatitis, chronic rhinosinusitis, and allergic rhinitis.
Drazdauskaite G, Layhadi JA, Shamji MH, 2021, Mechanisms of Allergen Immunotherapy in Allergic Rhinitis, CURRENT ALLERGY AND ASTHMA REPORTS, Vol: 21, ISSN: 1529-7322
- Author Web Link
- Cite
- Citations: 53
Agache I, Akdis C, Akdis M, et al., 2021, EAACI Biologicals Guidelines-Recommendations for severe asthma, ALLERGY, Vol: 76, Pages: 14-44, ISSN: 0105-4538
- Author Web Link
- Cite
- Citations: 110
Bousquet J, Anto JM, Bachert C, et al., 2021, ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice., Allergy, Vol: 76, Pages: 168-190, ISSN: 0105-4538
Digital anamorphosis is used to define a distorted image of health and care that may be viewed correctly using digital tools and strategies. MASK digital anamorphosis represents the process used by MASK to develop the digital transformation of health and care in rhinitis.It strengthens the ARIA change management strategy in the prevention and managementof airway disease. The MASK strategy is based on validated digital tools. Using the MASK digital tool and the CARAT online enhanced clinical framework, solutions for practical steps of digital enhancement of care are proposed.
Kirtland ME, Tsitoura DC, Durham SR, et al., 2020, Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy, FRONTIERS IN IMMUNOLOGY, Vol: 11, ISSN: 1664-3224
- Author Web Link
- Cite
- Citations: 45
Sokolowska M, Lukasik ZM, Agache I, et al., 2020, Immunology of COVID-19: Mechanisms, clinical outcome, diagnostics, and perspectives-A report of the European Academy of Allergy and Clinical Immunology (EAACI), ALLERGY, Vol: 75, Pages: 2445-2476, ISSN: 0105-4538
- Author Web Link
- Cite
- Citations: 106
Klimek L, Hoffmann HJ, Kalpaklioglu AF, et al., 2020, In-vivo diagnostic test allergens in Europe: A call to action and proposal for recovery plan-An EAACI position paper, ALLERGY, Vol: 75, Pages: 2161-2169, ISSN: 0105-4538
- Author Web Link
- Cite
- Citations: 18
Kirtland M, Vila-Nadal G, Tsitoura D, et al., 2020, Effects of toll-like receptor 7 on dendritic cells and B cells in inducing tolerogenic responses during allergic inflammation: A proof of concept study, European-Academy-of-Allergology-and-Clinical-Immunology Digital Congress (EAACI), Publisher: WILEY, Pages: 99-99, ISSN: 0105-4538
Oluwayi K, Bluemchen K, Beyer K, et al., 2020, Early clinical development plan for a novel virus like particle displaying Ara h 2 for the subcutaneous treatment of peanut allergy, European-Academy-of-Allergology-and-Clinical-Immunology Digital Congress (EAACI), Publisher: WILEY, Pages: 105-105, ISSN: 0105-4538
Hoof I, Shamji MH, Andersen PS, 2020, Multiomic approaches to study B cells: Sequencing, cytometry, imaging, and beyond Reply, JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, Vol: 146, Pages: 457-458, ISSN: 0091-6749
- Author Web Link
- Cite
- Citations: 1
Radauer C, Parkin R, Tang J, et al., 2020, YoaJ, an expansin-like protein from Bacillus subtilis, is a non-allergenic structural homologue of the major grass pollen allergen Phl p 1, European-Academy-of-Allergology-and-Clinical-Immunology Digital Congress (EAACI), Publisher: WILEY, Pages: 159-160, ISSN: 0105-4538
Layhadi JA, Golebski K, Bal SM, et al., 2020, Grass pollen sublingual immunotherapy drives the generation of functional IL-10-producing innate lymphoid cells that are associated with clinical benefit: An RDBPC study, European-Academy-of-Allergology-and-Clinical-Immunology Digital Congress (EAACI), Publisher: WILEY, Pages: 45-46, ISSN: 0105-4538
Parkin R, Laisuan W, Sanver D, et al., 2020, Evaluating a method validation to deplete, purify and determine the function of IgG4, IgA1 and IgA2 antibodies induced following sublingual immunotherapy in patients with allergic rhinitis, European-Academy-of-Allergology-and-Clinical-Immunology Digital Congress (EAACI), Publisher: WILEY, Pages: 131-131, ISSN: 0105-4538
Zhu R, Sharif H, Laisuan W, et al., 2020, Establishing a Th2 and Tfh cell exhaustion in vitro model using TCR Signaling to test T cell anergy during immunotherapy, European-Academy-of-Allergology-and-Clinical-Immunology Digital Congress (EAACI), Publisher: WILEY, Pages: 132-133, ISSN: 0105-4538
Sharif H, Fear D, Laisuan W, et al., 2020, IL-10+T follicular helper cells (CXCR5+PD-1+CD4+TFH10) promote immune tolerance and regulate b cell function following allergen immunotherapy: A proof-of-concept cross-sectional study, European-Academy-of-Allergology-and-Clinical-Immunology Digital Congress (EAACI), Publisher: WILEY, Pages: 46-46, ISSN: 0105-4538
Varricchi G, Bencivenga L, Poto R, et al., 2020, The emerging role of T follicular helper (T<sub>FH</sub>) cells in aging: Influence on the immune frailty, AGEING RESEARCH REVIEWS, Vol: 61, ISSN: 1568-1637
- Author Web Link
- Cite
- Citations: 30
Shamji MH, Akdis CA, Barber D, et al., 2020, EAACI Research and Outreach Committee: Improving standards and facilitating global collaboration through a Research Excellence Network, ALLERGY, Vol: 75, Pages: 1899-1901, ISSN: 0105-4538
- Author Web Link
- Cite
- Citations: 3
Lenormand M, Layhadi J, Moya R, et al., 2020, Targeting IL-10-producing regulatory B cells with a novel hypoallergenic depigmented and polymerized phleum pratense candidate for allergen immunotherapy in seasonal allergic rhinitis, European-Academy-of-Allergology-and-Clinical-Immunology Digital Congress (EAACI), Publisher: WILEY, Pages: 98-99, ISSN: 0105-4538
Ferastraoaru D, Bax HJ, Bergmann C, et al., 2020, AllergoOncology: ultra-low IgE, a potential novel biomarker in cancer-a Position Paper of the European Academy of Allergy and Clinical Immunology (EAACI), CLINICAL AND TRANSLATIONAL ALLERGY, Vol: 10
- Author Web Link
- Cite
- Citations: 30
Hoof I, Schulten V, Layhadi JA, et al., 2020, Allergen-specific IgG+ memory B cells are temporally linked to IgE memory responses, Journal of Allergy and Clinical Immunology, Vol: 146, Pages: 180-191, ISSN: 0091-6749
BACKGROUND: Immunoglobulin E (IgE) are least abundant, tightly regulated and IgE producing B cells are rare. The cellular origin and evolution of IgE responses are poorly understood. OBJECTIVE: To investigate the cellular and clonal origin of IgE memory responses following mucosal allergen exposure by sublingual immunotherapy (SLIT). METHODS: In a randomized double-blind, placebo-controlled, time-course SLIT study, peripheral blood mononuclear cells (PBMCs) and nasal biopsies were collected from forty adults with seasonal allergic rhinitis at baseline, 4, 8, 16, 28 and 52 weeks. RNA was extracted from PBMCs, sorted B cells and nasal biopsies for VH repertoire sequencing. Moreover, monoclonal antibodies were derived from single B cell transcriptomes. RESULTS: Combining VH repertoire sequencing and single cell transcriptomics yielded direct evidence of a parallel boost of two clonally and functionally related B cell subsets of short-lived IgE+ plasmablasts and IgG+ memory B cells (termed IgGE). Mucosal grass pollen allergen exposure by SLIT resulted in highly diverse IgE and IgGE repertoires. These were extensively mutated and appeared relative stable as per heavy chain isotype, somatic hypermutations and clonal composition. Single IgGE + memory B cell and IgE+ pre-plasmablast transcriptomes encoded antibodies that were specific for major grass pollen allergens and were able to elicit basophil activation at very low allergen concentrations. CONCLUSION: For the first time, we have shown that upon mucosal allergen exposure, human IgE memory resides in allergen-specific IgG+ memory B cells. These rapidly switch isotype and expand into short-lived IgE+ plasmablasts and serve as a potential target for therapeutic intervention.
Patel K, Vila-Nadal G, Shah J, et al., 2020, Is pollen-food syndrome a frequent comorbidity in adults with irritable bowel syndrome?, ALLERGY, Vol: 75, Pages: 1780-1783, ISSN: 0105-4538
- Author Web Link
- Cite
- Citations: 6
Klimek L, Jutel M, Akdis C, et al., 2020, Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement, ALLERGY, Vol: 75, Pages: 1546-1554, ISSN: 0105-4538
- Author Web Link
- Cite
- Citations: 76
Larson D, Patel P, Salapatek AM, et al., 2020, Nasal allergen challenge and environmental exposure chamber challenge: A randomized trial comparing clinical and biological responses to cat allergen, JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, Vol: 145, Pages: 1585-1597, ISSN: 0091-6749
- Author Web Link
- Cite
- Citations: 19
Alvaro-Lozano M, Akdis CA, Akdis M, et al., 2020, Allergen Immunotherapy in Children User’s Guide, Pediatric Allergy and Immunology, Vol: 31, Pages: 1-101, ISSN: 0905-6157
Allergen immunotherapy is a cornerstone in the treatment of allergic children. The clinical efficiency relies on a well-defined immunologic mechanism promoting regulatory T cells and downplaying the immune response induced by allergens. Clinical indications have been well documented for respiratory allergy in the presence of rhinitis and/or allergic asthma, to pollens and dust mites. Patients who have had an anaphylactic reaction to hymenoptera venom are also good candidates for allergen immunotherapy. Administration of allergen is currently mostly either by subcutaneous injections or by sublingual administration. Both methods have been extensively studied and have pros and cons. Specifically in children, the choice of the method of administration according to the patient's profile is important. Although allergen immunotherapy is widely used, there is a need for improvement. More particularly, biomarkers for prediction of the success of the treatments are needed. The strength and efficiency of the immune response may also be boosted by the use of better adjuvants. Finally, novel formulations might be more efficient and might improve the patient's adherence to the treatment. This user's guide reviews current knowledge and aims to provide clinical guidance to healthcare professionals taking care of children undergoing allergen immunotherapy.
Agache I, Beltran J, Akdis C, et al., 2020, Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma, ALLERGY, Vol: 75, Pages: 1023-1042, ISSN: 0105-4538
- Author Web Link
- Cite
- Citations: 168
Agache I, Rocha C, Beltran J, et al., 2020, Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma, ALLERGY, Vol: 75, Pages: 1043-1057, ISSN: 0105-4538
- Author Web Link
- Cite
- Citations: 66
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.